SGLT2活性对胰高血糖素分泌无直接影响
本研究利用离体灌流大鼠胰腺模型,探讨SGLT2活性对胰高血糖素分泌的影响。结果显示,抑制SGLT1/2或添加其底物均不影响胰高血糖素输出,且SGLT2在大鼠、小鼠和人类胰岛及α细胞中表达极低或检测不到。结论认为SGLT2抑制剂治疗中血浆胰高血糖素升高不太可能源于对α细胞SGLT2的直接抑制。
要点
- 抑制SGLT1/2不影响离体灌流大鼠胰腺的胰高血糖素分泌。
- SGLT2在胰岛及α细胞中表达极低或检测不到。
- SGLT2抑制剂所致胰高血糖素升高可能继发于降糖效应。
核心结论
- SGLT2抑制剂治疗中血浆胰高血糖素升高不太可能由直接抑制α细胞SGLT2所致,而可能继发于其降糖效应下游。
研究设计与样本
- 采用离体灌流大鼠胰腺这一生理模型,研究SGLT2活性对胰高血糖素分泌的影响。
- 检测大鼠、小鼠和人类胰岛及小鼠和人类α、β、δ细胞中Slc5a2表达和SGLT2蛋白含量。
主要发现
- 葡萄糖从低浓度(3.5 mmol/l)升至髙浓度(10 mmol/l)后数分钟内,胰高血糖素输出下降三至五倍(4.0 ± 0.5 pmol/15 min vs 1.3 ± 0.3 pmol/15 min,p < 0.05)。
- 在低或高葡萄糖浓度下,用达格列净或根皮苷抑制SGLT1/2,或添加SGLT1/2底物α-甲基吡喃葡萄糖苷,胰高血糖素输出均未受影响(p = 0.29-0.99)。
- 胰岛素和生长抑素分泌(潜在旁分泌调节因子)也未受影响。
- 在大鼠、小鼠和人类胰岛及小鼠和人类α、β、δ细胞中,Slc5a2表达和SGLT2蛋白为边缘性或低于检测限。
临床怎么用
- 提示SGLT2抑制剂相关胰高血糖素升高并非α细胞直接作用,临床解读该现象时应考虑继发于降糖效应的可能。
局限性
- 研究主要基于离体灌流大鼠胰腺模型,种属差异及体内环境复杂性可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Sodium-glucose cotransporter (SGLT) 2 inhibitors constitute a new class of glucose-lowering drugs, but they increase glucagon secretion, which may counteract their glucose-lowering effect. Previous studies using static incubation of isolated human islets or the glucagon-secreting cell line α-TC1 suggested that this results from direct inhibition of alpha cell SGLT1/2-activity. The aim of this study was to test whether the effects of SGLT2 on glucagon secretion demonstrated in vitro could be reproduced in a more physiological setting. METHODS: We explored the effect of SGLT2 activity on glucagon secretion using isolated perfused rat pancreas, a physiological model for glucagon secretion. Furthermore, we investigated Slc5a2 (the gene encoding SGLT2) expression in rat islets as well as in mouse and human islets and in mouse and human alpha, beta and delta cells to test for potential inter-species variations. SGLT2 protein content was also investigated in mouse, rat and human islets. RESULTS: Glucagon output decreased three- to fivefold within minutes of shifting from low (3.5 mmol/l) to high (10 mmol/l) glucose (4.0 ± 0.5 pmol/15 min vs 1.3 ± 0.3 pmol/15 min, p < 0.05). The output was unaffected by inhibition of SGLT1/2 with dapagliflozin or phloridzin or by addition of the SGLT1/2 substrate α-methylglucopyranoside, whether at low or high glucose concentrations (p = 0.29-0.99). Insulin and somatostatin secretion (potential paracrine regulators) was also unaffected. Slc5a2 expression and SGLT2 protein were marginal or below detection limit in rat, mouse and human islets and in mouse and human alpha, beta and delta cells. CONCLUSIONS/INTERPRETATION: Our combined data show that increased plasma glucagon during SGLT2 inhibitor treatment is unlikely to result from direct inhibition of SGLT2 in alpha cells, but instead may occur downstream of their blood glucose-lowering effects.
引用
- Kuhre RE, Ghiasi SM, Adriaenssens AE, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia. 2019. PMID: 30903205. doi:10.1007/s00125-019-4849-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。